(Total Views: 808)
Posted On: 10/27/2020 11:09:31 AM
Post# of 154253
Doing a little research I found that the UK has 101,600 people living with HIV. At first, I scoffed at how small this population is.
But then I realized that HIV is not a 2 dose disease. That, this will be a recurring revenue stream for CYDY. So, my next question was how much revenue?
My memory isnt what it used to be, but I believe annual treatment of Leronlimab is expected to be around $50,000 per year? Someone correct me if I am wrong.
Does anyone have our royalty schedule handy?
Simple math for now, if $50,000 is correct and we net roughly 40%, we would profit $20,000 per patient per year.
If we are able to capture 10% of the UK marketshare, that equates to $200,000,000 in revenue per year.
Id say that would remedy our money woes.
But then I realized that HIV is not a 2 dose disease. That, this will be a recurring revenue stream for CYDY. So, my next question was how much revenue?
My memory isnt what it used to be, but I believe annual treatment of Leronlimab is expected to be around $50,000 per year? Someone correct me if I am wrong.
Does anyone have our royalty schedule handy?
Simple math for now, if $50,000 is correct and we net roughly 40%, we would profit $20,000 per patient per year.
If we are able to capture 10% of the UK marketshare, that equates to $200,000,000 in revenue per year.
Id say that would remedy our money woes.
(5)
(1)
